Drug intelligence / Profile preview

lambda carrageenan

Development stage
Unknown
Lead developer
Population Council
Administration
Intranasal, Topical, Vaginal
01

Overview

Lambda carrageenan is a natural sulfated polysaccharide derived from red seaweed (Rhodophyceae). Unlike kappa and iota carrageenans, lambda carrageenan contains three sulfate groups per disaccharide unit and lacks 3,6-anhydrogalactose, which prevents it from forming a rigid gel and allows it to remain as a highly viscous, soluble random coil in aqueous solutions. It acts as a broad-spectrum, virus-agnostic entry inhibitor. Its negatively charged ester sulfate groups bind via electrostatic interactions to positively charged viral surface proteins (such as the L1 capsid protein of HPV, gp120 of HIV-1, hemagglutinin of influenza, and the spike protein of SARS-CoV-2), physically blocking viral attachment and entry into host cells. It has been clinically evaluated in vaginal gel formulations (such as PC-503 and Divine 9) for the prevention of sexually transmitted infections, demonstrating significant protective efficacy against human papillomavirus (HPV) in Phase II trials, and is also being investigated for the prevention of respiratory viral infections.

Brand names
CarragenixDivine 9Divine9Divine-9
Other names
L-CRGlambda-CGNlambda-carrageenanλ-carrageenan
02

Targets

gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)HA (Hemagglutinin)HPV L1 (Human papillomavirus L1 capsid protein)SARS-CoV-2 spikeCD4 (T lymphocyte surface antigen)

Beyond the preview

Go deeper on lambda carrageenan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lambda carrageenan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call